Knut Elbers is Director of the Boehringer Ingelheim Corporate Venture Fund, where he has been involved in several investments. He served as board member of Okarios AG in Basel and is a board member of NBE Therapeutics and of AMAL Therapeutics since 2013 and 2014 respectively.
Knut joined Boehringer Ingelheim in 1995 in the international R&D department of the animal health business. From 1999 to 2008 he was heading the European vaccine research organisation for animal health. During his work at Boehringer Ingelheim Knut was involved in 12 patent applications and key development projects (Ingelvac PRRSV, Enterisol Ileitis, Ingelvac CircoFLEX) contributing significantly to the vaccine business success of the animal health business of Boehringer Ingelheim.
Knut studied Biology at the Eberhard-Karls-University of Tübingen, Germany with a specific focus on Virology and Immunology. He undertook his PhD at the Federal Institute for Viral Diseases in Tübingen focusing on protein processing during viral replication and pathogen/host interaction mechanism.